Daphnetin plus chemo for advanced ovarian cancer maintenance
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a combination of two drugs—daphnetin capsules and a standard chemotherapy (TC regimen)—as a targeted maintenance therapy after initial surgery for advanced ovarian cancer. The goal is to see if this treatment can help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage 3 or 4 ovarian cancer and have not had any chemotherapy or other treatment yet.
- You had surgery that removed all or almost all of the visible tumor (R0 or R1).
- You are generally healthy enough to be up and active (ECOG score 0 or 1).
- Your organs and bone marrow are working well enough.
- You are willing to provide a tumor sample from a past biopsy or surgery (or have a new one taken).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
This study tests a combination of two targeted therapies, fluzoparib (a PARP inhibitor) and apatinib (a blood vessel blocker), as maintenance treatment after initial chemotherapy for advanced ovarian cancer. The goal is to see if this combination helps keep the cancer from coming back longer than usual.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.